Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide

Johansson, 1982, Topical and systemic glucocorticoid potencies of budesonide, beclomethasone, dipropionate and prednisolone in man, Eur. J. Respir. Dis., 122, 74 Greenberg, 1994, Budesonide for the treatment of inflammatory bowel disease, Can. J. Gastroenterol., 8, 369, 10.1155/1994/956865 Edsbacker, 1987, Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects, Drug Metab. Dispos., 15, 403 Rutgeerts, 1994, A comparison of budesonide with prednisolone for active Crohn's disease, N. Engl. J. Med., 331, 842, 10.1056/NEJM199409293311304 Campieri, 1997, Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group, Gut, 41, 209, 10.1136/gut.41.2.209 Greenberg, 1994, Oral budesonide for active Crohn's disease. Inflammatory Bowel Disease Study Group, N. Engl. J. Med., 331, 836, 10.1056/NEJM199409293311303 Tremaine, 2002, Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States, Am. J. Gastroenterol., 97, 1748, 10.1111/j.1572-0241.2002.05835.x Ecker, 2003, Oral budesonide significantly improves water absorption in patients with ileostomy for Crohn's disease, Scand. J. Gastroenterol., 38, 288, 10.1080/00365520310000645a D'Haens, 1998, Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease, Aliment. Pharmacol. Ther., 12, 419, 10.1046/j.1365-2036.1998.00321.x Angulo, 2000, Oral budesonide in the treatment of primary sclerosing cholangitis, Am. J. Gastroenterol., 95, 2333, 10.1111/j.1572-0241.2000.02323.x Edsbacker, 2003, A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules, Aliment. Pharmacol. Ther., 17, 525, 10.1046/j.1365-2036.2003.01426.x Ryrfeldt, 1982, Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid, Eur. J. Respir. Dis., 122, 86 Nilsson, 1995, Dose-proportional kinetics of budesonide controlled ileal release capsules, Gastroenterology, 108, 885, 10.1016/0016-5085(95)27845-1 Naber, 1996, Pharmacokinetics of budesonide controlled ileal release capsules in active Crohn's disease, Gastroenterology, 110, 977 Lundin, 2001, Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease, Aliment. Pharmacol. Ther., 15, 45, 10.1046/j.1365-2036.2001.00910.x Cvetkovic, 1996, Prolonged release profile of entocort (budesonide) capsules, Scand. J. Gastroenterol., 31, 6 Cvetkovic, 1997, Intraluminal concentrations of budesonide following administration of Entocort capsules in subjects with ileostomy, Gut, 41, 222 Edsbacker, 1983, Metabolic pathways of the topical glucocorticoid budesonide in man, Drug Metab. Dispos., 11, 590 Hempfling, 2003, Pharmacokinetics and pharmacodynamic action of budesonide in early-and late-stage primary biliary cirrhosis, Hepatology, 38, 196, 10.1053/jhep.2003.50266 Seidegard, 2000, Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration, Clin. Pharmacol. Ther., 68, 13, 10.1067/mcp.2000.106895 Edsbacker, 2003, Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole, Aliment. Pharmacol. Ther., 17, 403, 10.1046/j.1365-2036.2003.01431.x AstraZeneca (Accessed 2003 Dec 1). Entocort EC (budesonide) capsules. Prescribing information [on-line]. Spencer, 1995, Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease, Drugs, 50, 854, 10.2165/00003495-199550050-00006 Thomsen, 1998, A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group, N. Engl. J. Med., 339, 370, 10.1056/NEJM199808063390603 Kane, 2002, The effectiveness of budesonide therapy for Crohn's disease, Aliment. Pharmacol. Ther., 16, 1509, 10.1046/j.1365-2036.2002.01289.x Bar-Meir, 1998, Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group, Gastroenterology, 115, 835, 10.1016/S0016-5085(98)70254-9 Herfarth, 2003, Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization, Int. J. Colorectal Dis., 19, 147, 10.1007/s00384-003-0529-5 Steinhart, 2002, Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial, Gastroenterology, 123, 33, 10.1053/gast.2002.34225 Lundin, 2003, Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease, Aliment. Pharmacol. Ther., 17, 85, 10.1046/j.1365-2036.2003.01386.x Kundhal, 2001, Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth, J. Pediatr. Gastroenterol. Nutr., 33, 75, 10.1097/00005176-200107000-00013 Levine, 2003, A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease, J. Pediatr. Gastroenterol. Nutr., 36, 248, 10.1097/00005176-200302000-00017 Summers, 1979, National Cooperative Crohn's Disease Study: results of drug treatment, Gastroenterology, 77, 847, 10.1016/0016-5085(79)90385-8 Greenberg, 1996, Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group, Gastroenterology, 110, 45, 10.1053/gast.1996.v110.pm8536887 Lofberg, 1996, Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one-year study, Gut, 39, 82, 10.1136/gut.39.1.82 Ferguson, 1998, Oral budesonide as maintenance therapy in Crohn's disease—results of a 12-month study. Global Budesonide Study Group, Aliment. Pharmacol. Ther., 12, 175, 10.1046/j.1365-2036.1998.00285.x Gross, 1998, Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group, Gut, 42, 493, 10.1136/gut.42.4.493 Green, 2001, Freedom Investigator Group, Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules, Aliment. Pharmacol. Ther., 15, 1331, 10.1046/j.1365-2036.2001.01055.x Simms, 2001, Budesonide for maintenance of remission in Crohn's disease, Cochrane Database Syst. Rev., 10.1002/14651858.CD002913 Hellers, 1999, Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group, Gastroenterology, 116, 294, 10.1016/S0016-5085(99)70125-3 Ewe, 1999, Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group, Eur. J. Gastroenterol. Hepatol., 11, 277, 10.1097/00042737-199903000-00011 Lofberg, 1996, Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis, Gastroenterology, 110, 1713, 10.1053/gast.1996.v110.pm8964395 Baert, 2002, Codali Brussels, Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up, Gastroenterology, 122, 20, 10.1053/gast.2002.30295 Bonderup, 2003, Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis, Gut, 52, 248, 10.1136/gut.52.2.248